Literature DB >> 10647094

Differential changes in brain and platelet 5-HT concentrations after steady-state achievement and repeated administration of antidepressant drugs in mice.

J C Alvarez1, M Sanceaume, C Advenier, O Spreux-Varoquaux.   

Abstract

The aim of the study was to compare in male NMRI mice the simultaneous evolution of blood serotonin (5-HT) concentrations, which correspond to 99% of platelet 5-HT content, and 5-HT parameters in the dorsal raphe, caudate nucleus and frontal cortex after clomipramine, fluoxetine and moclobemide treatments. After steady-state concentrations of the three compounds were reached, the 5-HT levels were significantly enhanced vs. saline-treated mice in the three brain areas studied. Tryptophan (TRP) levels in the three brain areas were significantly increased with clomipramine and fluoxetine but not with moclobemide. A significant decrease in the metabolite 5-hydroxyindoleacetic acid (5-HIAA) levels was observed only with moclobemide. After 14 days of treatment, 5-HT levels in all areas studied were found to be enhanced only with moclobemide while TRP and 5-HIAA levels were not different under the three drug regimes from those of controls. After 21 days of treatment, 5-HT levels were found enhanced only with moclobemide in the nerve terminal regions. An important depletion in platelet 5-HT content was observed after clomipramine and fluoxetine treatments at day 14 and day 21 and a significant increase was observed after moclobemide treatment at day 14 with a return to initial values after 21 days. Our results show significantly different effects between central and peripheral indices of 5-HT metabolism according to time and to the antidepressant assessed: (i) an enhancement of total tissue 5-HT levels in the three brain areas studied after steady-state achievement of the 3 antidepressants, (ii) the return to initial values of brain 5-HT levels after repeated administration of the two 5-HT re-uptake inhibitors, consistent with the presence of brain adaptative mechanisms, with a concomitant dramatic decrease of platelet 5-HT content and (iii) an apparent gradual attenuation of the brain and periphery MAOI-A effect induced by moclobemide with 5-HT levels remaining elevated only in 5-HT nerve terminal regions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10647094     DOI: 10.1016/s0924-977x(99)00048-6

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  6 in total

1.  Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment.

Authors:  John F Cryan; Michelle E Page; Irwin Lucki
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

2.  Chronic SSRI treatment exacerbates serotonin deficiency in humanized Tph2 mutant mice.

Authors:  William B Siesser; Benjamin D Sachs; Amy J Ramsey; Tatyana D Sotnikova; Jean-Martin Beaulieu; Xiaodong Zhang; Marc G Caron; Raul R Gainetdinov
Journal:  ACS Chem Neurosci       Date:  2012-10-01       Impact factor: 4.418

3.  Monoamine depletion by reuptake inhibitors.

Authors:  Marty Hinz; Alvin Stein; Thomas Uncini
Journal:  Drug Healthc Patient Saf       Date:  2011-10-20

4.  Acute fluoxetine treatment induces slow rolling of leukocytes on endothelium in mice.

Authors:  Nadine Herr; Maximilian Mauler; Thilo Witsch; Daniela Stallmann; Stefanie Schmitt; Julius Mezger; Christoph Bode; Daniel Duerschmied
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

5.  1-Methyl-1,2,3,4-tetrahydroisoquinoline, an endogenous Neuroprotectant and MAO inhibitor with antidepressant-like properties in the rat.

Authors:  Agnieszka Wąsik; Edyta Możdżeń; Jerzy Michaluk; Irena Romańska; Lucyna Antkiewicz-Michaluk
Journal:  Neurotox Res       Date:  2013-09-25       Impact factor: 3.911

6.  Serotonin transporter gene promoter methylation status correlates with in vivo prefrontal 5-HTT availability and reward function in human obesity.

Authors:  M Drabe; M Rullmann; J Luthardt; Y Boettcher; R Regenthal; T Ploetz; G A Becker; M Patt; C Schinke; F T Bergh; F Zientek; A Hilbert; A Bresch; W Fenske; M K Hankir; O Sabri; S Hesse
Journal:  Transl Psychiatry       Date:  2017-07-04       Impact factor: 6.222

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.